CO2023014093A2 - Formulaciones de l-asparaginasa - Google Patents
Formulaciones de l-asparaginasaInfo
- Publication number
- CO2023014093A2 CO2023014093A2 CONC2023/0014093A CO2023014093A CO2023014093A2 CO 2023014093 A2 CO2023014093 A2 CO 2023014093A2 CO 2023014093 A CO2023014093 A CO 2023014093A CO 2023014093 A2 CO2023014093 A2 CO 2023014093A2
- Authority
- CO
- Colombia
- Prior art keywords
- formulations
- asparaginase
- lbl
- asparagine
- disorders
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 title abstract 2
- 108010024976 Asparaginase Proteins 0.000 title abstract 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 abstract 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 201000011649 lymphoblastic lymphoma Diseases 0.000 abstract 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 abstract 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 abstract 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 229960001230 asparagine Drugs 0.000 abstract 1
- 235000009582 asparagine Nutrition 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
- C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
- C12Y305/01001—Asparaginase (3.5.1.1)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Genetics & Genomics (AREA)
- Inorganic Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163171429P | 2021-04-06 | 2021-04-06 | |
| PCT/US2022/071562 WO2022217231A1 (en) | 2021-04-06 | 2022-04-05 | Formulations of l-asparaginase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2023014093A2 true CO2023014093A2 (es) | 2023-10-30 |
Family
ID=81748398
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2023/0014093A CO2023014093A2 (es) | 2021-04-06 | 2023-10-23 | Formulaciones de l-asparaginasa |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP4319818A1 (https=) |
| JP (1) | JP2024515555A (https=) |
| KR (1) | KR20230165799A (https=) |
| CN (1) | CN117377494A (https=) |
| AR (1) | AR125301A1 (https=) |
| AU (1) | AU2022256071A1 (https=) |
| BR (1) | BR112023019862A2 (https=) |
| CA (1) | CA3213726A1 (https=) |
| CL (1) | CL2023002983A1 (https=) |
| CO (1) | CO2023014093A2 (https=) |
| MX (1) | MX2023011693A (https=) |
| WO (1) | WO2022217231A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022211829A1 (en) | 2021-03-30 | 2022-10-06 | Jazz Pharmaceuticals Ireland Ltd. | Dosing of recombinant l-asparaginase |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7985548B2 (en) | 2006-03-03 | 2011-07-26 | The United States Of America As Represented By The Department Of Health And Human Services | Materials and methods directed to asparagine synthetase and asparaginase therapies |
| KR102783452B1 (ko) * | 2016-06-01 | 2025-03-19 | 세르비에 아이피 유케이 리미티드 | 폴리알킬렌 옥시드-아스파라기나제의 제형, 및 그의 제조 및 사용 방법 |
| JP2021505661A (ja) * | 2017-11-30 | 2021-02-18 | ジャズ ファーマシューティカルズ アイルランド リミテッド | アスパラギナーゼを用いた治療法 |
| JP2022553399A (ja) * | 2019-10-25 | 2022-12-22 | ジャズ ファーマシューティカルズ アイルランド リミテッド | 組換えｌ－アスパラギナーゼ |
-
2022
- 2022-04-05 CN CN202280032191.2A patent/CN117377494A/zh active Pending
- 2022-04-05 KR KR1020237037007A patent/KR20230165799A/ko active Pending
- 2022-04-05 JP JP2023561628A patent/JP2024515555A/ja active Pending
- 2022-04-05 AU AU2022256071A patent/AU2022256071A1/en active Pending
- 2022-04-05 BR BR112023019862A patent/BR112023019862A2/pt unknown
- 2022-04-05 AR ARP220100846A patent/AR125301A1/es unknown
- 2022-04-05 MX MX2023011693A patent/MX2023011693A/es unknown
- 2022-04-05 WO PCT/US2022/071562 patent/WO2022217231A1/en not_active Ceased
- 2022-04-05 EP EP22724215.3A patent/EP4319818A1/en active Pending
- 2022-04-05 CA CA3213726A patent/CA3213726A1/en active Pending
-
2023
- 2023-10-05 CL CL2023002983A patent/CL2023002983A1/es unknown
- 2023-10-23 CO CONC2023/0014093A patent/CO2023014093A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2023002983A1 (es) | 2024-04-12 |
| KR20230165799A (ko) | 2023-12-05 |
| EP4319818A1 (en) | 2024-02-14 |
| MX2023011693A (es) | 2023-12-15 |
| JP2024515555A (ja) | 2024-04-10 |
| BR112023019862A2 (pt) | 2023-11-07 |
| WO2022217231A1 (en) | 2022-10-13 |
| AR125301A1 (es) | 2023-07-05 |
| CN117377494A (zh) | 2024-01-09 |
| AU2022256071A1 (en) | 2023-10-19 |
| CA3213726A1 (en) | 2022-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2023003068A1 (es) | Compuestos, composiciones y métodos para el tratamiento de trastornos | |
| CL2020002914A1 (es) | Métodos y composiciones para tratar el cáncer | |
| MX2024006824A (es) | Degradadores de la proteina transductora de se?al y activadora de la transcripcion 3 (stat3) y usos de los mismos. | |
| MX2019002750A (es) | Derivados de pirazolopiridina como moduladores de cinasa 1 progenitora hematopoyetica (hpk1) y usos de los mismos para tratamiento de cancer. | |
| MX2022001061A (es) | Agentes de interleuquina-2 y usos de los mismos. | |
| CL2018003316A1 (es) | Compuestos para la inhibición de k-ras y para el tratamiento del cáncer. (divisional solicitud 201702786) | |
| MX2021015992A (es) | Azacitidina en combinación con venetoclax, gilteritinib, midostaurina u otros compuestos para tratamiento de leucemia o síndrome mielodisplásico. | |
| PE20181330A1 (es) | Dinucleotidos ciclicos para tratar condiciones asociadas con actividad del estimulador de genes del interferon (sting) tales como cancer | |
| CL2019002368A1 (es) | Composiciones y métodos para el tratamiento de cáncer. | |
| MX2020010469A (es) | Inhibidores del atf6 y sus usos. | |
| MX2018005315A (es) | Composiciones y metodos para el tratamiento del cancer. | |
| CO2021002691A2 (es) | Composiciones y métodos para editar el gen hidroxiácido oxidasa 1 (hao1) para tratar la hiperoxaluria primaria tipo 1 (ph1) | |
| MX2020003594A (es) | Inhibidores de la quinasa p38 que reducen la expresión de dux4 y de los genes corriente abajo para el tratamiento de fshd. | |
| MX390503B (es) | Compuesto de pirimidina fusionada o sal del mismo. | |
| BR112018001853A2 (pt) | métodos para tratamento de um distúrbio e para melhoria do tratamento de um distúrbio | |
| CO2022000481A2 (es) | Inhibidores de enzimas | |
| MX2023005591A (es) | Metodos de tratamiento de enfermedades y trastornos. | |
| CL2025000194A1 (es) | Construcciones de arni para inhibir expresión de scap y sus usos | |
| CO2022015185A2 (es) | Tratamientos con radiación ultravioleta | |
| CO2024010771A2 (es) | Compuestos con estructura en t formada por al menos cuatro ciclos para usar en el tratamiento del cáncer y otras indicaciones | |
| PE20242222A1 (es) | Agentes de interferencia de arn de sarm1 | |
| CO2023014093A2 (es) | Formulaciones de l-asparaginasa | |
| PA8597501A1 (es) | Derivados azabiciclicos de piridiloximetilo y bencisoxazol | |
| MX2022008843A (es) | Metodos para tratar cancer con inhibidores de farnesiltransferasa. | |
| CL2023003090A1 (es) | Combinaciones de composiciones terapéuticas y usos para tratar cánceres |